The influence of tumor cell density on cellular accumulation of doxorubicin or cisplatin in vitro
Abstract
The effect of tumor cell density on the cellular pharmacokinetics of doxorubicin (DXR) and cisplatin (CDDP) was studied using MOLT-3 human acute lymphoblastic leukemia cells. As determined by the MTT assay, the growth-inhibitory effect of DXR was approx. 40 times lower when cell density was increased from 10(6) to 10(8) cells/ml (positive inoculum effect), whereas little or no influence of cell density was observed in CDDP-induced cell-growth inhibition. As measured by high-performance liquid chromatography using a fluorescence detector, the cellular accumulation of DXR showed 6- and 18-fold decreases after 1 h incubation when the cells were concentrated from 10(6) to 10(7) and 10(8) cells/ml, respectively. Only at low cell density (10(6) cells/ml) did the amount of DXR in the cells increase with increasing exposure times of up to 6 h. The DXR concentration in the supernatant that was separated from a cell suspension showing a density of 10(8) cells/ml fell to 20% of that obtained at 10(6) cells/ml. The metabolites of DXR, including Adriamycinol and Adriamycinone, were not detectable in the cell extracts or supernatants at any cell density examined. In contrast, the cellular accumulation of CDDP calculated from the platinum concentration, which was measured with a flameless atomic absorption spectrophotometer, was essentially identical at all cell densities examined; moreover, extension of the exposure period resulted in a linear increase in the amount of CDDP in the cells. C…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Higher cell densities are characterized by more pronounced paracrine signaling and contact inhibition.
“In addition to the statistical decrease in drug accumulation (Takemura et al., 1991; Schildknecht et al., 2015), higher cell densities are characterized by more pronounced paracrine signaling and contact inhibition.”
From In Vitro research Reproducibility: Keeping up High Standards (2019) · cites this paper as Takemura et al., 1991
Cited by
Sorted by citations
In Vitro research Reproducibility: Keeping up High Standards
Hirsch, C., & Schildknecht, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01484 · Cited by 161 · see citing works
- Authors
- Takemura, Y., Kobayashi, H., Miyachi, H., Hayashi, K., Sekiguchi, S., & Ohnuma, T.
- Affiliations
- National Defense Medical College (JP)
- Tokai University (JP)
- National Defense Medical College Hospital (JP)
- Mount Sinai Hospital (US)
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 1991
- Volume
- 27
- Issue
- 6
- Pages
- 417-422
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2030184878
- Cited by
- 29
- References
- 0
- Citations by year
- 2022: 1 · 2019: 1 · 2016: 1 · 2012: 1
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Keywords
- tumor cell density, doxorubicin, cisplatin, MOLT-3 cells, acute lymphoblastic leukemia, pharmacokinetics, drug metabolites, growth inhibition
- MeSH terms
- Cell Count, Cell Division, Chromatography, High Pressure Liquid, Cisplatin, Doxorubicin, Humans, Naphthacenes, Platinum, Spectrophotometry, Atomic, Tumor Cells, Cultured, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review